Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity

Uriach

Status and phase: Completed; Phase 2

Conditions: Insulin Resistance

Treatments: Drug: Triflusal (DCI)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00162799

ICO5TRI/2/01

Details and patient eligibility

About

To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal.

Full description

Double-blind, randomized, cross-over (three periods) with two dose levels of triflusal, placebo-controlled.

Interventions: treatment periods Triflusal 600 mg/d, 15 days Triflusal 900 mg/d , 15 days placebo, 15 days

Washout period: 30 days

Sex: All

Ages: 35 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Ages 35 to 60 years old

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind